STOCK TITAN

Precision Optics Corporation (POCI) 424B Filings

POCI NASDAQ

Here are the 424B prospectus supplements from Precision Optics Corporation, Inc. (POCI) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 424B covers the supplement that carries the terms of a priced offering, so if you follow POCI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full POCI filings page.

Rhea-AI Summary

Precision Optics Corporation, Inc. is conducting a primary offering of 2,777,777 shares of common stock at a public offering price of $3.60 per share via a prospectus supplement dated March 27, 2026. The company expects net proceeds of approximately $9.3 million to be used for working capital and general corporate purposes.

The offering permits the underwriters to purchase an additional 416,667 shares within 45 days. The prospectus lists 7,733,857 shares outstanding as of March 23, 2026 and shows expected common shares outstanding after the offering of 10,511,634 (or 10,928,301 if the option is exercised).

Rhea-AI Summary

Precision Optics Corporation, Inc. is offering shares of common stock and, at investors' election, pre-funded warrants exercisable for one share at an exercise price of $0.01 per share. The company states its common stock trades on Nasdaq under the symbol POCI and cites a public float market value of $36.3 million computed as of March 25, 2026 based on 7,733,857 shares outstanding as of such date, of which 6,110,561 were held by non-affiliates.

The prospectus supplement describes customary underwriter terms, including a 45-day option to purchase additional shares, lock-up arrangements, and a representative’s warrant equal to 5.0% of shares sold. Net proceeds are expected to be used for working capital and general corporate purposes. The offering disclosure highlights immediate dilution risk, exercise limitations for pre-funded warrants tied to 4.99% or 9.99% beneficial ownership caps, and that the pre-funded warrants will not be listed on any exchange.